RxDoctor Payments Data

Michael Cohen

Towson, MDNPI 1619984937

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 93.9% of it on its own, with 6 other manufacturers making up the rest.

$276,873in general payments, 2019–2025

Across 314 payments — averaging $881.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260K
  • Davol Inc.$11K
  • Motiva USA, LLC$3K
  • Tepha Inc$2K
  • Galderma Laboratories, L.p.$160
  • Integra Lifesciences Corporation$52
  • plus $49 from 1 others
$18,728in research payments, 2019–2025

Across 4 payments — averaging $4682.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tepha Inc$19K

What the payments were for

  • Consulting fees$89,97532%
  • Speaking & faculty fees$159,68158%
  • Travel & lodging$18,2697%
  • Food & beverage$8,8613%
  • Gifts$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)278$260,107
Davol Inc.16$11,186
Motiva USA, LLC10$3,068
Tepha Inc2$2,250
Galderma Laboratories, L.p.5$160
Integra Lifesciences Corporation2$52
Mentor Worldwide LLC1$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →